AIM ImmunoTech Inc. (AIM)

NYSEAMERICAN: AIM · Real-Time Price · USD

0.5200

-0.0060 (-1.14%)

At close: Apr 23, 2026, 4:00 PM EDT

0.5200

0.00 (0.00%)

After-hours: Apr 23, 2026, 6:30 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Clinical Development of New Drug Therapies Based on Natural Immune System	88.00K	170.00K	202.00K	141.00K	135.00K
Clinical Development of New Drug Therapies Based on Natural Immune System Growth	-48.24%	-15.84%	43.26%	4.44%	-17.18%
Total	88.00K	170.00K	202.00K	141.00K	135.00K
Total Growth	-48.24%	-15.84%	43.26%	4.44%	-17.18%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	88.00K	170.00K	-	-	-
United States Growth	-48.24%	-	-	-	-
Total	88.00K	170.00K	-	-	-
Total Growth	-48.24%	-	-	-	-

Source: S&P Global Market Intelligence.